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Enhanced protection from renal ischemia: Reperfusion injury Novel therapeutic interventions for preventing or re-
with A2A-adenosine receptor activation and PDE 4 inhibition. ducing renal tissue injury following ischemia-reperfusion
Background. We previously demonstrated in rats and mice remain a focus of intense research. One potential approachthat agonists of A2A-adenosine receptors (A2A-ARs) reduce renal in reducing injury from ischemia-reperfusion is throughinjury following ischemia-reperfusion. We now extend these
the activation of A2A-adenosine receptors (A2A-ARs).studies and examine the effects of ATL-146e (formerly DWH-
146e), an A2A-AR agonist, and rolipram, a type IV phosphodi- ATL-146e (previously referred to as DWH-146e), an
esterase (PDE 4) inhibitor, on murine renal injury following A2A-AR agonist, has a higher affinity and selectivity for
ischemia-reperfusion. human and rat A2A-ARs than does CGS21680, a widelyMethods. C57BL/6 mice were treated with rolipram, ATL-
used selective A2A agonist [1–3]. ATL-146e binds selec-146e, or both compounds combined and were subjected to
tively to human A2A-ARs with 50 times higher affinityrenal ischemia for 32 minutes and reperfusion for 24 to 48 hours.
In vitro studies were performed on suspended and adhering than CGS21680. A similar relative potency was noted in
human neutrophils. studies of cAMP accumulation in transfected HEK-293
Results. Continuous delivery of rolipram or ATL-146e during cells expressing canine A2A-ARs (ED50 4 nmol/L) [2].reperfusion reduced renal injury in a dose-dependent manner.
We previously showed that A2A agonists reduce renalMaximal protection was observed when ATL-146e was infused
tissue injury when administered prior to and immediatelyfor six hours during reperfusion. Elevated plasma creatinine
and myeloperoxidase activity produced by ischemia-reperfu- after the onset of reperfusion following ischemia [2–4].
sion were reduced by rolipram (0.1 ng/kg/min) and ATL-146e A2A agonists may inhibit inflammation by effects on many
(10 ng/kg/min) by up to approximately 60% and 70%, respec- different cell types that are thought to contribute to isch-tively. Co-infusion of both compounds produced a maximum
emia-reperfusion injury. We demonstrated that A2A-ARreduction of plasma creatinine of approximately 90% and my-
activation following renal ischemia-reperfusion reducedeloperoxidase activity. In vitro studies on suspended and adher-
ing human neutrophils demonstrated that selective stimulation neutrophil accumulation in renal tissue [3]. This effect
of A2A-ARs by ATL-146e increased cAMP accumulation, re- appeared to be correlated with a decrease in the expres-
duced oxidative activity of activated neutrophils, and decreased sion of P-selectin and intercellular adhesion molecule-1activated neutrophil adherence. These responses were potenti-
(ICAM-1) [3], which are endothelial adhesion moleculesated by rolipram.
that participate in renal ischemia-reperfusion injury [5–9].Conclusions. We conclude that the combined infusion of
ATL-146e and rolipram leads to enhanced renal tissue protec- Such effects suggested that A2A agonists reduced endo-
tion from ischemia-reperfusion by mechanisms that may in- thelial adhesion molecule expression by binding to A2A
clude reduced neutrophil adherence/recruitment and release receptors expressed on endothelial cells. Alternatively,of reactive oxygen species.
A2A agonists may have reduced expression of endothelial
cell adhesion molecule indirectly by binding to and stabi-
lizing tissue-resident inflammatory cells. Activation of
A2A-ARs on neutrophils leads to potent anti-inflamma-
tory effects [10–14].
Type IV phosphodiesterase (PDE 4) inhibitors suchKey words: rolipram, ATL-146e, neutrophil adherence, reactive oxy-
gen species, acute renal failure, oxidative burst. as rolipram are being developed as anti-inflammatory
compounds [15]. These inhibitors are known to reduceReceived for publication October 4, 2000
inflammation by decreasing release of cytokines suchand in revised form December 22, 2000
Accepted for publication January 8, 2001 as interleukin-1b (IL-1b) and tumor necrosis factor-a
(TNF-a) and increasing the release of IL-10 [15]. WhenÓ 2001 by the International Society of Nephrology
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Table 1. Control and experimental groupsinfused in rats subjected to endotoxin-mediated acute
renal failure, PDE 4 inhibitors stabilize renal function Compound administration
Group ng/kg/min[16, 17].
1 VehicleOne cellular mechanism by which A2A agonists may
2 ROL (0.1)reduce renal injury is through an increase in cAMP in
3 ROL (1)
inflammatory cells. A2A-ARs are coupled to adenylyl cy- 4 ROL (10)
5 ATL-146e (0.1)clase via stimulatory G proteins (Gs protein), and when
6 ATL-146e (0.5)activated, they increase cellular cAMP levels. PDE 4
7 ATL-146e (1)
inhibitors reduce inflammation by increasing cAMP ac- 8 ATL-146e (10)
9 ROL (0.001)cumulation by inhibiting cAMP degradation [18]. Thus,
10 ROL (0.005)we hypothesized that A2A-agonists reduce inflammation 11 ROL (0.01)
through an increase in cAMP, and that the coadministra- 12 ATL-146e (0.1) 1 ROL (0.001)
13 ATL-146e (0.5) 1 ROL (0.005)tion of an A2A-agonist and a PDE 4 inhibitor, such as
14 ATL-146e (1) 1 ROL (0.01)rolipram, would produce greater tissue protection from
15 ATL-146e (10) 1 ROL (0.1)
ischemia-reperfusion injury than either compound alone.
Compounds were administered 5 hours prior to the ischemic period in allOur results demonstrate that coadministration of roli- groups except as noted in the Results section. All kidneys were subjected to 32
minutes of ischemia and 24 hours of reperfusion. ROL is rolipram.pram and ATL-146e is more effective than either agent
alone in inhibiting neutrophil oxidative activity of human
neutrophils and in inhibiting ischemia-reperfusion injury
in mouse kidneys.
and mice were then cradled in a plexiglass animal re-
strainer to maintain the position of the catheter during
METHODS reperfusion. Beginning immediately after onset of reper-
fusion, mice were given a bolus of vehicle or ATL-146eSurgery and experimental protocol
(60 ng/kg IP), and vehicle or ATL-146e was infusedSurgical methods employed in the current study have
continuously at a rate of 1 mL/min (10 ng/kg/min) for 2,been described previously [2]. Briefly, C57BL/6 mice (7
4, 6, or 24 hours via syringe pump (model 55-5920; Southto 8 weeks of age, 18 to 28 g; Hilltop Laboratory Animals,
Natick, MA, USA).Scottsdale, PA, USA) were used for all experiments.
Alzett osmotic minipumps (model 1003D; Alza Corp., Plasma creatinine
Palo Alto, CA, USA) containing vehicle, ATL-146e, or
From blood samples obtained by cardiac puncture,rolipram (prepared in phosphate-buffered saline con-
plasma creatinine concentration was determined usingtaining ,0.01% dimethylsulfoxide) were inserted subcu-
a colorimetric assay according to the manufacturer’s pro-taneously under vaporized halothane anesthesia five hours
tocol (Sigma Chemical, St. Louis, MO, USA).prior to reperfusion (Halothan Vapor 19.1, Germany).
Following pump implantation, mice were anesthetized
Myeloperoxidase activity
with ketamine [100 mg/kg, intraperitoneally (IP)], xyla-
Mouse kidneys were removed and immediately homog-zine (10 mg/kg, IP), and acepromazine [1 mg/kg, intramus-
enized in 10 volumes of ice-cold 50 mmol/L KPO4 buffer,cularly (IM)] and were subjected to bilateral flank inci-
pH 7.4, using a Tekmar tissue grinder. The homogenatesions. Renal pedicles were identified and cross-clamped
was centrifuged at 15,000 3 g for 15 minutes at 48C, andfor 32 minutes. Surgical wounds were closed with metal
the resultant supernatant was discarded. The pellet wasstaples, and mice were returned to cages for 24 hours.
washed twice, resuspended in 10 volumes of ice-cold 50Following 24 hours of reperfusion, animals were re-anes-
mmol/L KPO4 buffer with 0.5% hexadecyltrimethylam-thetized. Blood was obtained by cardiac puncture, and
monium bromide and sonicated. The suspension waskidneys were removed for various analyses. Our previous
subjected three times to freeze/thaw, sonicated for 10studies demonstrated similar degrees of renal protection
seconds, and centrifuged at 15,000 3 g for 15 minutes atwhen ATL-146e treatment was initiated five hours prior
48C. The supernatant was added to an equal volume ofto ischemia or immediately after the onset of reperfusion
a solution consisting of o-dianisidine (10 mg/mL), 0.3%[2]. Table 1 summarizes the control and experimental
H2O2, and 45 mmol/L KPO4, pH 6.0. Absorbance wasgroups.
measured at 460 nm over a period of five minutes [19].In some experiments, the duration of ATL-146e infu-
sion was varied by delivery of the compound via a subcu-
Isolation of neutrophilstaneously placed catheter. PE 10 catheters were inserted
Human polymorphoneutrophils (PMNs) were isolatedsubcutaneously with the animals under anesthesia,
from heparinized (10 U/mL) venous blood by a one-attached to a 3 cc syringe, and sutured in place. Mouse
kidneys were then subjected to the ischemia protocol, step Ficoll-hypaque separation [20]. Neutrophil isolation
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medium was purchased from ICN Biochemicals (Aurora, the curve) in the presence of a compound compared with
TNF-a–primed fMLP-stimulated control samples.OH, USA). The resulting PMN preparation contained
approximately 98% PMNs, and .95% were viable as
Neutrophil adhesion assaydetermined by trypan blue exclusion. Following separa-
tion, PMNs were washed three times with Hank’s bal- Adhesion assays were performed with fibrinogen-
anced salt solution (HBSS) and resuspended in HBSS. coated Costar 96-well flat bottomed cell culture cluster
plates (Corning, NY, USA) as described previously in
Cyclic AMP this article (“Cyclic AMP”). Human PMNs were incu-
bated with the fluorescent dye calcein-AM (0.1 mg/mL;Cyclic AMP (cAMP) was measured in PMNs adhering
to 24-well tissue culture plates coated with human fi- Molecular Probes, Inc., Eugene, OR, USA) for 30 min-
utes at 378C under 5% CO2. Calcein-loaded PMNs werebrinogen (5 mg/mL in 1.5% sodium bicarbonate, 0.5 mL/
well; Sigma) overnight at 378C in 5% CO2 [14]. The wells incubated for 15 minutes with or without 0.001 to 100
nmol/L ATL-146e, 10 nmol/L ZM241385, and 100 nmol/Lwere washed two times at 378C with 200 mL of normal
saline solution immediately before the addition of un- rolipram. Just prior to addition to the plate, 10 U/mL
TNF-a was added to the calcein-loaded PMNs (100 mL/stimulated human PMNs. PMNs (3 to 4 3 106/0.5 mL)
were incubated within a well of the coated plate for 45 well; 5 3 106 cells/mL), and then the treated PMNs were
placed into the fibrinogen-coated wells [21]. Plates wereminutes in 0.5 mL of HBSS containing 0.1% human
serum albumin and 1 U/mL adenosine deaminase covered with aluminum foil and incubated for 30 minutes
under 5% CO2 at 378C [21]. Nonadherent cells were(Sigma) 6 10 U/mL TNF-a (specific activity 5 600 pg/U;
a gift from Dainippon Pharmaceutical Co. Ltd., Osaka, removed with four washes of 200 mL warm saline and
resuspended in 200 mL of HBSS–0.1% human serumJapan), 6 3 to 300 nmol/L ATL-146e, and 6 300 nmol/L
rolipram (Berlex Laboratories, Cedar Knolls, NJ, USA). albumin. The fluorescence was measured using emission
and excitation wavelengths of 538 and 485 nm, respec-Following incubation, 0.5 mL 0.2 N HCl was added to
the wells, and the incubation continued for 45 minutes tively (Victor 1420 Multilabel Counter using the Wallac
Workstation software). A standard curve of fluorescencemore at room temperature to extract the cAMP. The
samples were then centrifuged at 2000 3 g for 10 minutes was determined for the PMN concentrations between
5 3 105 and 1 3 104 PMNs per sample with each experi-to remove cell debris. Half milliliter cell-free samples
were frozen for cAMP analysis in the University of Vir- ment. The percentage of TNF-activated adherent PMNs
was calculated as: (relative fluorescence after washingginia Radioimmunoassay Core Laboratory (Charlottes-
ville, VA, USA). procedure/relative fluorescence of TNF activated cells
before the washing procedure) 3 100%.
Suspended neutrophil oxidative activity as measured
by chemiluminescence Superoxide release from PMNs adhering to a
biological surfaceWe evaluated the bioactivity of ATL-146e on the oxi-
dative activity of neutrophils primed with TNF-a and Superoxide release was measured as described pre-
viously but with modifications [22]. PMNs (2 3 106/mL)stimulated with f-met-leu-phe (fMLP) as measured by
luminol-enhanced chemiluminescence. Chemilumines- were preincubated for 15 minutes at 378C in 0.45 mL of
HBSS containing 0.1% human serum albumin and 1cence is dependent on both superoxide production and
mobilization of the granule enzyme myeloperoxidase U/mL adenosine deaminase, 6 100 nmol/L rolipram, 6
0.1 to 100 nmol/L ATL-146e, and 6 100 nmol/L ZM(MPO). Light is emitted from unstable high-energy oxy-
gen species generated by activated neutrophils. Purified 241385.
Following incubation, 120 mmol/L cytochrome CPMNs were incubated in HBSS containing 0.1% 1 mL
human serum albumin, 1 U/mL adenosine deaminase (Sigma) and 0.062 mg/mL catalase (Sigma) were added 6
10 U/mL TNF-a. Aliquots of cell suspensions (200 mL)(Sigma), and 10 U/mL TNF-a for 30 minutes at 378C in
a shaking water bath. Some PMNs were incubated during were immediately transferred to duplicate wells of a 96-
well flat-bottomed tissue culture plate that had been coatedTNF-a priming 6 0.01 to 100 nmol/L ATL-146e, 6 100
nmol/L to 1 mmol/L rolipram, 6 the protein kinase A with human fibrinogen as described before. An enzyme-
linked immunosorbent assay (ELISA) plate reader (Ti-(PKA) inhibitor H-89 (0.1 to 10 mmol/L; Calbiochemical,
La Jolla, CA, USA) and 6 10 nmol/L ZM241385. Lumi- tertek, McLean, VA, USA) was used to measure the opti-
cal density at 550 nm of the samples relative to matchednol-enhanced (1 3 104 mol/L; Sigma) fMLP-stimulated
(1 mmol/L; Sigma) chemiluminescence was read with a samples before and after two hours of incubation (378C,
5% CO2) with superoxide dismutase (200 U/mL; Sigma).Chronolog Photometer (Chronolog Corp., Havertown,
PA, USA) at 378C for eight minutes. Chemiluminescence Superoxide dismutase-inhibitable superoxide (nmol) re-
leased in 0 to 120 minutes was calculated [23].is reported as the relative peak light emitted (height of
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Statistical analysis
A randomized block design was used to analyze the
data. In this design, the day of the procedure was consid-
ered as a block factor. Analysis of variance (ANOVA)
for the randomized block design and post hoc analysis
(Bonferroni) were performed. In some analyses, paired
and unpaired Student t-tests were used. In the in vitro
PMN assays data values (mean, SEM, EC50) were deter-
mined using Graph Pad Prism (San Diego, CA, USA).
P , 0.05 was used to determine significance.
RESULTS
Dose- and time-dependent reduction of renal injury
following ischemia-reperfusion using ATL-146e
Previously, we demonstrated that ATL-146e reduced
renal ischemia-reperfusion injury when administered ei-
ther before or immediately after the ischemic period [2].
The optimal dose and duration of treatment, however,
are unknown. Beginning with a treatment regimen known
to be effective, we sought to determine the dose of ATL-
146e necessary for optimal tissue protection following
ischemia-reperfusion injury. Vehicle (group 1) or ATL-
146e (groups 5 through 8) was administered beginning
five hours prior to the 32-minute ischemic period, and
was continued for 24 hours during the reperfusion pe-
riod. There was a dose-dependent effect of ATL-146e.
As observed previously, ischemia-reperfusion injury pro-
duced an increase in plasma creatinine that was reduced
maximally by 60 to 70% by the A2A-agonist treatment Fig. 1. Dose- and time-dependent reduction in renal injury in mice
infused with ATL-146e subjected to ischemia-reperfusion. (A) Mouse(Fig. 1A and Table 2) [2]. The greatest effect was ob-
kidneys were subjected to 32 minutes of ischemia and 24 hours ofserved with a 1 to 10 ng/kg/min dose. Using the maxi- reperfusion. Vehicle or ATL-146e (0.1, 0.5, 1, and 10 ng/kg/min) was
mally effective dose of ATL-146e (10 ng/kg/min), a 77% administered continuously via osmotic minipump beginning 5 hours
prior to ischemia and continuing through the 24-hour period of reperfu-reduction in plasma creatinine was observed at 48 hours
sion. Plasma creatinine was measured following 24 hours of reperfusion.
(Table 2). (B) Kidneys were subjected to ischemia-reperfusion (32 minutes of
ischemia/24 hours of reperfusion), and vehicle or 10 ng/kg/min ATL-The time course of the ATL-146e effect was evaluated.
146e was infused continuously (via catheter inserted subcutaneously)Following the onset of reperfusion, mice were adminis-
beginning with the onset of reperfusion and continuing for 2, 4, 6, or
tered vehicle or 10 ng/kg/min ATL-146e for 2, 4, 6, or 24 hours during the reperfusion period. Plasma creatinine was measured
following 24 hours of reperfusion. Plasma creatinine levels are expressed24 hours. As shown in Figure 1B, the magnitude of pro-
as means 6 SE. *P , 0.05, **P , 0.001 when compared with vehicletection, as assessed by a reduction in plasma creatinine,
(N 5 4 to 5 per group).
correlated with the duration of treatment. The greatest
degree of protection was observed when the compound
was administered during the first six hours of reperfusion.
first sought to determine whether rolipram, a PDE 4No further significant benefit was observed when treat-
inhibitor, reduces renal injury when administered priorment was extended to 24 hours.
to and during ischemia-reperfusion injury. Vehicle
PDE 4 inhibition reduces renal injury following (group 1) or rolipram at 0.1 (group 2), 1.0 (group 3), or
ischemia-reperfusion and potentiates the renal 10 ng/kg/min (group 4) was administered via osmotic
protective effect of A2A-agonist treatment minipumps beginning five hours prior to ischemia and
continuing through 24 hours of reperfusion. RolipramThe cellular mechanism underlying the anti-inflam-
alone reduced renal injury, as assessed by a reductionmatory effect of A2A-agonists may involve signaling
in elevated plasma creatinine levels in a dose-dependentthrough cAMP/PKA. We reasoned that by inhibiting
manner. Plasma creatinine values for vehicle and roli-degradation of cAMP, a more pronounced effect of A2A
activation might be achieved. Thus, in initial studies, we pram at 0.1, 1.0, and 10 ng/kg/min were 1.30 6 0.10, 0.78 6
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Table 2. Effect of combined A2A-agonist and Type IV phosphodiesterase inhibitor on plasma creatinine following
ischemia/reperfusion injury
D P value
A B C ATL-146e 1
Groupsa Vehicle Rolipram ATL-146e rolipram B vs. D C vs. D
ATL 10/ROL 0.1
24 hours (N 5 9) 1.3960.16 0.6860.13 (0.60) 0.5360.10 (0.71) 0.2860.04 (0.88) ,0.001 ,0.001
48 hours (N 5 7) 1.5660.23 0.6360.11 (0.65) 0.4560.07 (0.77) 0.2860.04 (0.89) ,0.001 ,0.05
ATL 1/ROL 0.01
24 hours (N 5 5) 1.3060.10 0.7260.10 (0.50) 0.5960.08 (0.60) 0.2860.08 (0.84) ,0.01 ,0.05
ATL 0.5/ROL 0.005
24 hours (N 5 5) 1.5860.08 1.4760.09 (0.08) 1.2260.07 (0.25) 1.0260.05 (0.38) ,0.001 ,0.01
ATL 0.1/ROL 0.001
24 hours (N 5 5) 1.5360.13 1.4260.12 (0.08) 1.3160.13 (0.16) 1.2360.15 (0.21) NS NS
Values are means 6 SE of plasma creatinine (mg/dL). Values in parentheses are fractional reduction in plasma creatinine compared to vehicle. Data were analyzed
by ANOVA followed by Bonferroni correction for multiple comparisons. Abbreviations are: ATL, ATL-146e; ROL, rolipram.
a Groups are identified by dose of ATL and ROL in ng/kg/min and number of hours of reperfusion following ischemia at which time blood samples were taken
0.12, 0.51 6 0.14, and 1.13 6 0.18 mg/dL, respectively Effect of PDE 4 inhibition and A2A-AR activation on
myeloperoxidase activity(N 5 5 per group, P 5 0.002, one-way ANOVA). Com-
pared with vehicle-treated mice, treatment with rolipram Our prior study showed that ischemia-reperfusion in-
at doses of 0.1, 1.0, and 10 ng/kg/min (N 5 5 per group) jury caused a pronounced infiltration of neutrophils in
led to reductions in plasma creatinine of 58, 77, and 43%, the kidney, and ATL-146e reduced this neutrophil accu-
respectively. Upon further examination of these data in mulation [3]. The degree of neutrophil accumulation can
5 of 5 mice, rolipram infused at 1.0 ng/kg/min led to a be assessed by measuring the activity of MPO, an enzyme
greater reduction in creatinine than the highest dose of that is present in neutrophils and in which the activity
correlates with the degree of ischemia-reperfusion injury10 ng/kg/min (P , 0.05, one-way ANOVA).
[3]. To extend these previous findings, we sought to deter-Next, a series of experiments was performed using a
mine whether the combination of rolipram and ATL-146erange of ATL-146e and rolipram at doses starting well
produced a greater reduction in neutrophil accumula-below the effective renal protective dose of each com-
tion, as measured by MPO activity in kidney homoge-pound. These compounds were administered beginning
nates, than either compound alone. Treatment with roli-five hours prior to ischemia and continued through 24
pram alone (group 2), like ATL-146e alone (group 8),hours of reperfusion. The purpose was to determine
significantly reduced the increase in MPO activity pro-whether the combined effect of treatment with ATL-
duced by ischemia-reperfusion injury when compared146e and rolipram on reducing renal injury was greater
with vehicle-treated mice (group 1). Co-administrationthan either compound alone (Fig. 2 and Table 2). The
of maximally effective doses of ATL 10 and ROL 0.1administration of rolipram (ROL; 0.001 ng/kg/min;
(group 15) in mice subjected to ischemia-reperfusiongroup 9) or ATL-146e (ATL; 0.1 ng/kg/min; group 5)
injury led to a further decrease in MPO activity that wasalone or in combination (group 12) in mice subjected to
greater than either compound alone (Fig. 3).renal ischemia-reperfusion had no significant effect on
plasma creatinine when compared with vehicle (group ATL-146e alone or in combination with rolipram
1). Higher doses of ROL, ATL, and the combination of inhibits activated human neutrophil adherence
ROL 1 ATL led to a dose-dependent reduction in injury The administration of ATL-146e alone or in combina-
as compared with vehicle treatment. Fractional reduc- tion with rolipram is associated with a reduction of neu-
tion of plasma creatinine for ATL 0.5/ROL 0.005 (group trophil accumulation in kidneys subjected to ischemia-
13, 0.38 6 0.03 mg/dL) was greater than in 5/5 mice reperfusion (Fig. 3). Such an effect may be mediated in
treated with ATL 0.5 alone (group 6, 0.25 6 0.02 mg/dL, part by effects of these compounds on inflammatory cells
P , 0.01) and 5/5 mice treated with ROL 0.005 alone or endothelial cells. To determine whether ATL-146e
(group 10, 0.08 6 0.01 mg/dL, P , 0.001). Higher doses and rolipram alone or in combination may have direct
of the combination of ATL and ROL (groups 14 and effects on neutrophils to regulate neutrophil adherence
15) produced quantitatively similar results, and the effect factors, we studied neutrophil adherence to biological
was greater than either compound alone (groups 2, 7, 8, surfaces. This method permits a direct assessment of the
and 11). Combining maximally effective doses of ATL independent effect of ATL-146e/rolipram on neutrophil
and ROL demonstrates enhanced efficacy in reducing factors that regulate adherence. Therefore, we sought to
determine (1) whether ATL-146e by binding to A2A-ARsrenal ischemia-reperfusion injury.
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Fig. 2. Enhanced protection from ischemia-
reperfusion injury in mice coadministered
ATL-146e and rolipram. Kidneys were sub-
jected to ischemia-reperfusion. Vehicle, roli-
pram alone, ATL-146e alone, or a combination
of rolipram and ATL-146e was administered
via osmotic minipumps beginning five hours
prior to reperfusion and continuing through
the reperfusion period in the doses shown.
Values are mean 6 SE of fractional inhibition
in plasma creatinine compared with vehicle
treatment. Plasma creatinine values and statis-
tics are shown in Table 2.
had a direct effect on neutrophils to decrease neutrophil
adhesion to a biological surface and to decrease the re-
sulting oxidative burst of these adhering neutrophils, and
(2) whether rolipram could potentiate the anti-inflam-
matory effect of ATL-146e on activated neutrophil ad-
herence and oxidative burst. Calcein-loaded PMNs were
activated with 10 U/mL TNF-a, and then the treated
PMNs were placed into the fibrinogen-coated wells. The
effect of ATL-146e and rolipram on adherence of human
PMNs is shown in Figure 4A. In the absence of rolipram,
0.01 to 100 nmol/L ATL-146e reduced activated neutro-
phil adherence by a maximum of approximately 25%.
The addition of rolipram (100 nmol/L), at a concentra-
tion that produced relatively little effect alone, potenti-
ated the effect of ATL-146e by reducing neutrophil ad-
herence by approximately 75%. The effect of ATL-146e
on the activated neutrophil adherence was blocked in
the presence of ZM243185 (100 nmol/L), a selective A2A
antagonist (Fig. 4B).
ATL-146e and rolipram inhibit activated human
Fig. 3. Enhanced reduction in myeloperoxidase (MPO) activity in mice
neutrophil oxidative activity in suspended andcoadministered ATL-146e and rolipram. Kidneys were subjected to
ischemia-reperfusion. Vehicle, 0.1 ng/kg/min rolipram, 10 ng/kg/min adherent human PMNs
ATL-146e, or the combination of 0.1 rolipram and 0.1 and 10 ng/kg/
Previous studies in neutrophil suspensions and neutro-min ATL-146e, respectively, was administered via osmotic minipumps
(times of administration as in Fig. 2). MPO activity was measured in phils adherent to biological surfaces indicated differences
kidneys harvested at the end of the reperfusion period. Values are in neutrophil oxidative activity in response to TNF-a [24].mean 6 SE (N 5 7 for each group). *P , 0.001 vs. vehicle, rolipram
or ATL-146e; #P , 0.001 vs. vehicle. Therefore, to study the direct effects of ATL-146e and
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with 0.01 to 100 nmol/L ATL-146e had reduced oxidative
activity compared with controls. The effect of ATL alone
on oxidative activity in suspended cells (Fig. 5A) was
much greater than the effect observed on adherent cells
(Fig. 5B). However, in both suspended and adhering
PMNs, 100 nmol/L rolipram synergistically augmented
the inhibitory effect of ATL-146e on the oxidative burst
(Fig. 5 A and B, respectively). In suspended cells (Fig.
5A), the dose response curve for ATL-146e was shifted
markedly to the left, and the IC50 for ATL-146e was
reduced sixfold by the addition of rolipram (from 0.451
to 0.073 nmol/L in the absence and presence of rolipram),
whereas in adherent cells (Fig. 5B), the IC50 was reduced
34-fold (6.974 and 0.209 nmol/L in the absence and pres-
ence of rolipram, respectively). To determine whether
the effects of ATL-146e on activated neutrophil oxida-
tive burst were mediated by A2A receptors, ZM243185
was used. The effect of ATL-146e on activated neutro-
phil adherence oxidative burst in suspended (Fig. 5C)
or adhering cells (Fig. 5D) was blocked in the presence
of 100 nmol/L ZM243185.
ATL-146e and rolipram inhibit activated human
neutrophil oxidative activity in adherent and
suspended human PMNs via cAMP/PKA
To determine the contribution of the cAMP/PKA
pathway as a signaling pathway to neutrophil oxidative
activity, the effect of ATL-146e on cAMP accumulation
was determined in activated neutrophils. Incubation of
TNF-activated human neutrophils with 3 to 300 nmol/L
ATL-146e led to a dose-dependent increase in cAMP
(Fig. 6A), an effect that was enhanced in the presence
of rolipram. To determine whether the effect of ATL-
146e on human neutrophil oxidative activity was medi-
ated by an effect on cAMP-dependent PKA activity, the
Fig. 4. ATL-146e alone or in combination with rolipram inhibits acti- selective PKA inhibitor, H-89 (0.1 to 10 mmol/L) was
vated neutrophil adherence of human polymorphoneutrophils (PMNs). used [25]. Although H-89 had no effect on neutrophilThe adherence of isolated human neutrophils to biological surfaces was
oxidative activity in the absence of ATL-146e, it effec-measured as described in the Methods section. (A) The effects of 0.01
to 100 nmol/L ATL-146e on neutrophil adherence to biological surfaces tively blocked inhibition of the oxidative burst by 10
were assessed in the presence (j) and absence (s) of 100 nmol/L nmol/L ATL-146e (Fig. 6B). These results suggest thatrolipram. The percentage of TNF-activated adherent PMNs was deter-
the decrease in neutrophil oxidative activity producedmined by measuring the fluorescence of calcein-loaded neutrophils be-
fore and after washing the plates to remove nonadherent cells. (B) by the selective activation of A2A-ARs expressed on neu-
Specificity of the effects of 0.01 to 100 nmol/L ATL-146e on neutrophil trophils may be due to increased cAMP and activationadherence was determined by using 100 nmol/L ZM241385 (m) or no
of PKA and could provide a mechanism for the reductionZM241385 (s). All studies were done in the presence of 100 nmol/L
rolipram (N 5 9 to 22). Values are mean 6 SE in both panels. of renal injury observed with ATL-146e in ischemia-
reperfusion.
DISCUSSIONrolipram on neutrophil oxidative activity, the effects of
these compounds were examined in two experimental The purpose of this study was to test the hypothesis
conditions: suspended and adherent PMNs. In suspended that agonists of A2A adenosine receptors and phosphodi-
human neutrophils, cells were primed with 10 U/mL esterase inhibitors produce an enhanced reduction of
TNF-a and stimulated with 1 mmol/L fMLP, and luminol- renal tissue injury when administered together. The ra-
enhanced chemiluminescence was assayed as an index tionale for these studies stems from (1) our previous
work demonstrating potent reduction of renal injuryof oxidative activity. Samples of neutrophils incubated
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Fig. 5. ATL-146e and rolipram potently re-
duce oxidative activity in adherent and sus-
pended human PMNs. The effect of ATL-146e
on neutrophil oxidative activity on suspen-
sions of PMNs is shown in (A and C), and the
effect on adherent PMNs is shown in (B and
D). The method for measurement of neutro-
phil oxidative activity is described in the Meth-
ods section. Symbols in A and B are: (s) no
rolipram; (j) rolipram. Symbols in C and D
are: (m) ZM243185; (s) no ZM243185. (A) The
bioactivity of ATL-146e on TNF-a–primed,
fMLP-stimulated human PMN oxidative ac-
tivity 6 100 nmol/L rolipram as measured by
luminol-enhanced chemiluminescence. Chemi-
luminescence is reported as relative peak light
emitted (5 height of the curve), compared
with TNFa-primed fMLP-stimulated control
samples (N 5 5). (B) The effect of 0.1 to 100
nmol/L ATL-146e on the oxidative activity
of adherent neutrophils was examined 6 100
nmol/L rolipram. Oxidative activity is ex-
pressed as the release of superoxide from cells
incubated with cytochrome c and stimulated
with recombinant human TNF-a (N 5 5). (C)
The specificity of effect of ATL-146e on neu-
trophil oxidative activity in suspended PMNs
was determined 6 ZM243185 (N 5 6). (D)
The specificity of effect of ATL-146e on neu-
trophil oxidative activity in adherent PMNs
was determined 6 100 nmol/L ZM243185. All
studies were done in the presence of rolipram
(N 5 9 to 22). Values in all panels are given
as mean 6 SE.
when the novel A2A-agonist ATL-146e is administered indicate that infusion of compound during the first six
hours of the reperfusion period produces maximal tissueeither before or immediately after the onset of reperfu-
sion [2], and (2) work by others demonstrating a reduc- protection. No further benefit was observed when the
infusion was continued for 24 hours; however, tissuetion of renal injury following infusion of a PDE 4 inhibi-
tor [16, 17]. Because both types of compounds act along protection was maintained during the remainder of the
24-hour period. We cannot exclude the possibility thatdifferent pathways to increase intracellular cAMP accu-
mulation, we evaluated the effects of combination ther- prolonged infusion of 24 hours produced a measurable
beneficial effect, if a marker more sensitive than plasmaapy and found that treatment with both compounds to-
gether has a greater effect in reducing renal injury than creatinine had been used to assess the extent of injury
and function (glomerular filtration rate, urinary tubulareither compound alone. Furthermore, this reduction in
tissue injury may be due, in part, to direct effects of ATL- enzymes, etc.). It can be concluded from these experi-
ments that maximal protection is observed when 1 to 10146e and rolipram on neutrophils to decrease oxidative
activity. ng/kg/min of ATL-146e is maintained for six hours dur-
ing the reperfusion period. These findings have impor-We previously demonstrated a profound reduction in
injury when ATL-146e administration was initiated be- tant clinical implications. The low dose of ATL-146e and
the short duration of treatment will likely minimize anyfore ischemia or immediately after the ischemic period
and continued through the reperfusion period [2, 3]. In untoward side effects that are potentially associated with
the use of this agent.mice subjected to ischemia-reperfusion, we observed a
maximal reduction in plasma creatinine of up to 60% Cyclic nucleotide phosphodiesterases are responsible
for the degradation of cGMP and cAMP [26]. The PDEfollowing treatment for 24 to 48 hours. We now extend
those studies by examining the dose response character- family includes a list of specific phosphodiesterases that
currently include 11 isoforms [15]. The PDE 4 familyistic of ATL-146e and the treatment duration in reducing
ischemia-reperfusion injury. ATL-146e infusions of 1 comprises four genetically different subtypes, and inhibi-
tors of this group of enzymes produce anti-inflammatoryand 10 ng/kg/min during the 24-hour reperfusion period
produced a similar reduction of plasma creatinine of effects [15]. In studies of the kidney, inhibitors of PDE
4 have been found to reduce renal injury in models ofapproximately 70 and 80%, respectively. Lower doses
were less effective, however. Our current studies also acute renal failure [16, 17] and glomerulonephritis [27].
Okusa et al: A2A-adenosine receptor activation and PDE 4 inhibition in renal injury2122
Fig. 7. Dose-dependent reduction in renal injury in mice infused with
rolipram and subjected to ischemia/reperfusion. A portion of the data
from Table 2 is redrawn to show the dose response relationship between
fractional reduction in plasma creatinine and 0.001 to 0.1 ng/kg/min
doses of rolipram. Mice were subjected to 32 minutes of ischemia and
24 hours of reperfusion. Vehicle or rolipram was administered via
osmotic minipumps beginning five hours prior to reperfusion and contin-
uing through the reperfusion period in the doses shown. Values are
mean 6 SE of the fractional change in plasma creatinine from vehicle
treatment. Numbers and statistics are shown in Table 2.
renal ischemia-reperfusion, infusion of rolipram at 0.01
to 0.1 ng/kg/min reduced plasma creatinine by 50 to
60%. This reduction in renal injury was associated with
a significant reduction of inflammatory cell accumula-
tion, as assessed by MPO activity. MPO is an enyzme
primarily present in neutrophils as well as in mononu-
clear cells. Thus, its activity likely represents contribu-
tions from both cell types. It is striking that these doses
are 105 to 106 lower than those used previously in studiesFig. 6. ATL-146e and rolipram potently reduce oxidative activity in
human PMNs via cAMP/PKA. (A) The effect of ATL-146e on cAMP with Ro20-1724 [16, 17], and therefore, our observations
accumulation in activated human PMNs is shown. PMNs were incubated
may reflect the effect of doses that have primarily anti-(3 to 5 3 106 PMNs/0.5 mL/sample) with 3 to 300 nmol/L ATL-146e
and without (s) or with (m) 300 nmol/L rolipram for 45 minutes at inflammatory rather than hemodynamic properties. Al-
378C. Reactions were stopped, and cAMP was determined by radioim- though these two studies used different PDE 4 inhibitors,
munoassay (N 5 5). (B) The effect of H-89, a PKA inhibitor, on
both Ro20-1724 (IC50 2 mmol/L) and rolipram (IC50 0.8activated human PMNs is shown. Neutrophils were incubated with 0.1
to 10 mmol/L H89 without (s) or with (m) ATL-146e, and oxidative mmol/L) have similar affinities for PDE 4. It is interesting
activity was measured (N 5 6). Values are mean 6 SE in all panels. to note in our preliminary dose-response studies using
higher doses of rolipram (0.1, 1.0, and 10 ng/kg/min), the
highest dose was associated with a smaller reduction in
plasma creatinine than the intermediate dose. This resultInfusion of 10 mg/kg/min Ro20-1724, a selective and po-
suggests that higher doses of rolipram may produce othertent PDE 4 inhibitor, attenuated the observed reduction
effects in addition to PDE 4 inhibition.of renal blood flow and glomerular filtration and im-
Both ATL-146e and rolipram increase cAMP by dif-proved survival in endotoxin-mediated acute renal fail-
ferent mechanisms. Whereas rolipram reduces cAMPure [16, 17]. Although these observations could represent
degradation by blocking PDE 4, ATL-146e increasesa direct effect on maintaining favorable renal hemody-
cAMP synthesis through its action on stimulatory gua-namics, they could also reflect the benefits of reducing
nine nucleotide proteins and activation of adenylyl cy-inflammation within the kidney. By increasing cAMP in
clase. Thus, we hypothesized that the combination ofinflammatory cells, PDE 4 inhibitors decrease inflam-
the two compounds would be more potent in reducingmation [15, 22].
renal ischemia-reperfusion when coadministered. TheOur studies demonstrate a dose-dependent effect of
results indicate that the co-administration of ATL-146erolipram to reduce the injury associated with ischemia-
reperfusion (Fig. 7 and Table 2). In mice subjected to and rolipram produced a potent inhibition of renal injury
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that was greater than either compound alone (Fig. 2 and T-cells, which have been largely overlooked, may play
an important role in ischemia-reperfusion injury [37].Table 2).
There are several potential mechanisms that may con- Although our studies focused on neutrophils, ATL-146e
could also mediate protective effects, in part through itstribute to the renal protective effect of the combination
of ATL-146e and rolipram. First, both compounds in action on mononuclear cells. Given the obvious limita-
tions of sample size in mice, we chose to use humanhigh doses are vasodilators. A2A agonists, through the
activation of A2A-ARs, produce medullary vasodilation neutrophils because of the ease in obtaining large enough
quantities to perform in vitro studies. This study found[28]. However, at low doses (4 ng/kg/min), ATL-146e
has no effect on systemic blood pressure and heart rate that ATL-146e reduced neutrophil oxidative activity, an
effect that was potentiated in the presence of rolipram[2]. Thus, an even lower dose of ATL-146e (1 ng/kg/
min) is unlikely to have significant systemic hemody- (Fig. 5 A, B). Thus, the pronounced renal protection
observed with the combined infusion of ATL-146e andnamic effects. Ro20-1724 at doses of 10 mg/kg/min pro-
duced significant effects on renal blood flow and glomer- rolipram may be mediated, in part, by a direct effect on
neutrophils to decrease oxidative activity. Moreover, theular filtration rate [16, 17]; however, our doses of
rolipram were 105 to 106 lower. Although systemic hemo- effect was blocked in the presence of H-89, a PKA inhibi-
tor, suggesting that the effect was mediated by cAMPdynamic parameters were not measured, rolipram is un-
likely to produce effects at these doses. Our studies did (Fig. 6B).
In kidneys subjected to ischemia-reperfusion, we dem-not include measurement of regional blood flow in the
kidney. Although there was no effect on systemic hemo- onstrated that the combined administration of ATL-146e
and rolipram had a greater effect to reduce MPO activitydynamics, we cannot exclude a favorable effect to in-
crease medullary circulation. Such an effect could in- than either compound alone. An effect of ATL-146e
and/or rolipram to decrease neutrophil adhesion andcrease oxygenation to an area that is relatively hypoxic.
It is possible that these compounds could increase medul- accumulation in kidneys subjected to ischemia-reperfu-
sion may be mediated by direct effects on neutrophilslary flow by two mechanisms: These compounds alone
or in combination may improve medullary circulation or by effects on endothelial cells to regulate the expres-
sion of adhesion molecules. Evidence for the latter stemsby a direct effect on renal vasculature. Additionally, it
is possible that by reducing inflammatory cell infiltration, from studies that show that ischemia-reperfusion in-
creases endothelial cell adhesion molecule expression,capillary plugging is reduced in the vasa recta in the
outer stripe of the outer medulla. Direct microcirculatory an effect that is blocked by infusion of ATL-146e [3].
To determine whether ATL-146e and rolipram alonestudies could provide additional important information
on the mechanism of tissue protection by A2A agonists or combined may have direct effects on neutrophils to
regulate neutrophil adherence factors, we studied neu-and type IV PDE inhibitors.
Second, both compounds are known to produce robust trophil adherence to biological surfaces, a method that
permits a direct assessment of the independent effect ofeffects on inflammatory responses. It is well known that
activated neutrophils or endothelial cells release and re- ATL-146e/rolipram on neutrophil. These studies demon-
strate that ATL-146e alone decreased neutrophil adher-spond to adenosine, an effect that appears to be mediated
by A2A-ARs [10–13]. Activation of A2A-ARs expressed ence. Moreover, this effect by ATL-146e on neutrophil
adherence was markedly potentiated by the addition ofon activated neutrophils reduces the release of reactive
oxygen metabolites [12, 29–32], and adenosine may also rolipram. Taken together with our previous study [3],
our results suggest that ATL-146e and rolipram decreaseinterfere with neutrophil adherence to endothelial cells
[33]. PDE 4 inhibitors also have known anti-inflamma- adherence by altering both endothelial and neutrophil
adherence factors. Such an effect on neutrophils couldtory effects, which is due, in part, to the prominent ex-
pression of a low Km cAMP specific member of family be explained by ATL-146e’s ability to decrease the
heightened activated neutrophil expression of CD11b/of PDE in inflammatory cells [34].
To determine whether the reduction in plasma creati- CD18. However, studies using a high concentration (1
mmol/L) of a less selective A2 agonist, 59N-ethylcarbox-nine, elicited by ATL-146e in mice subjected to ischemia-
reperfusion could be due in part to a direct action on amidoadenosine (NECA), failed to show regulation of
CD11b/CD18 expression [38]. Thus, the mechanism re-neutrophils, we performed in vitro studies on isolated
human neutrophils. Our studies focused on the participa- sponsible for the regulation of neutrophil adherence by
ATL-146e and rolipram is largely unknown.tion of neutrophils as targets of A2A-agonist action. Al-
though a number of studies demonstrated the pathophys- The therapeutic possibilities for the use of ATL-146e
or other highly selective agonists of A2A-ARs are quiteiological role of neutrophils in ischemia-reperfusion
injury [5], controversy still exists as not all studies support apparent from the foregoing discussion. First, ATL-146e
is capable of maximally reducing renal injury at ex-the role of neutrophils in ischemic renal injury [35, 36].
Recent evidence indicates that in addition to neutrophils, tremely low concentrations that are not known to pro-
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